Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Generic · Inhalation solution

Tobramycin 75 mg/mL inhalation solution price what pharmacies pay, and what you should

There is no weekly pharmacy acquisition cost for tobramycin 75 mg/ml inhalation solution this week. The makers, package codes, recalls and label are below.

What did you pay for tobramycin 75 mg/ml inhalation solution? Share it.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Supply status: shortages & recalls

In shortage1 product is short or being discontinued
6 ongoing recalls27 recalls on record, latest Mar 20, 2024

Shortages

  • Tobramycin Sulfate, Injection, 80 mg/2 mL (40 mg/mL); 2 mL Multiple Dose Glass Fliptop Vial (NDC 0409-3578-01)Hospira, Inc., a Pfizer Company · Being discontinued Jul 17, 2026 · Updated Jul 17, 2026Discontinuation of the manufacture of the drug

In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.

Recalls

Showing the 6 most relevant of 27 - all recalls.

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

Every manufacturer and package code

3 companies sell tobramycin 75 mg/ml inhalation solution under 3 package codes (NDCs).

All 3 package codes

A dash means no weekly price for that maker's packages. Which maker your pharmacy stocks usually doesn't change what you pay, but you can ask.

Other tobramycin strengths and forms

Strength and formPer unitPharmacies pay4 weeks52 weeks
3 mg/mL eye drops$1.10$5.48 / 5 mL-1.1%+7.2%
60 mg/mL inhalation solution$1.05$295.34 / 280 mL-2.7%-21.4%
40 mg/mL injection$0.9279$46.40 / 50 mL+11.6%+14.3%

Official label & what changed

Last changedFebruary 14, 2024
Version3 of 3
EffectiveFeb 7, 2024
Read the label

These highlights do not include all the information needed to use TOBRAMYCIN for injection safely and effectively. See full prescribing information for TOBRAMYCIN for injection.TOBRAMYCIN for Injection, for intravenous use Initial U.S. Approval: 1975

This drug has a boxed warning

WARNING: NEPHROTOXICITY, OTOTOXICITY AND EMBRYO-FETAL TOXICITY

WARNING: NEPHROTOXICITY, OTOTOXICITY, NEURO MUSCULAR BLOCKADE AND FETAL HARM

See full prescribing information for complete boxed warning.

Nephrotoxicity

Tobramycin for Injection may cause acute kidney injury. Monitor renal function and serum tobramycin concentrations in all patients. Reduce the dose or discontinue the Tobramycin for Injection if renal impairment occurs. (5.1)

Ototoxicity

Tobramycin for Injection may cause irreversible auditory and vestibular toxicity. Monitor for symptoms of ototoxicity, and for renal function and serum tobramycin levels in all patients. Reduce the dose or discontinue the Tobramycin for Injection if impairment of renal function occurs. Discontinue Tobramycin for Injection if ototoxicity occurs. (5.2)

Neuromuscular Blockade

Aminoglycosides have been associated with neuromuscular blockade. During therapy with Tobramycin for Injection, monitor for adverse reactions associated with neuromuscular blockade, particularly in high-risk patients (5.5)

Embryo-Fetal Toxicity

Tobramycin for Injection and other aminoglycosides can cause fetal harm when administered to a pregnant woman. Apprise pregnant women of the potential hazard to the fetus. (5.3, 8.1)

Nephrotoxicity

Tobramycin for Injection can result in acute kidney injury, including acute renal failure. Risk factors that may contribute to nephrotoxicity include tobramycin accumulation (increasing serum trough levels), high peak concentrations (above 12 mcg/mL), total cumulative dose, advanced age, volume depletion and concurrent or sequential use of other nephrotoxic drugs. Avoid concurrent or sequential use of other potentially nephrotoxic drugs. Monitor serum tobramycin levels and renal function in all patients during drug treatment. Reduce the dose or discontinue the Tobramycin for Injection if renal impairment occurs

[see Warnings and Precautions

(5.1)].

Ototoxicity

Tobramycin for Injection can cause irreversible auditory and vestibular toxicity that may continue to develop after the drug has been discontinued. Risk factors include high serum concentrations, prolonged therapy, renal impairment, concurrent and sequential use of other nephrotoxic or ototoxic drugs (e.g. aminoglycosides), and extremes of age. Avoid concurrent or sequential use with other potentially ototoxic drugs. Monitor for signs and symptoms of auditory and vestibular toxicity. Reduce the dose or discontinue the Tobramycin for Injection if renal impairment occurs. Discontinue the Tobramycin for Injection if ototoxicity occurs.

[see Warnings and Precautions (5.2)].

Neuromuscular Blockade

Aminoglycosides have been associated with neuromuscular blockade. During therapy with Tobramycin for Injection, monitor for adverse reactions associated with neuromuscular blockade, particularly in high-risk patients, such as patients with underlying neuromuscular disorders (including myasthenia gravis) or in patients concomitantly receiving neuromuscular blocking agents

[see Warnings and Precautions (5.5)].

Embryo-Fetal Toxicity

Tobramycin and other aminoglycosides can cause fetal harm when administered to a pregnant woman. If Tobramycin for Injection is used during pregnancy or if the patient becomes pregnant while taking tobramycin, apprise the patient of the potential hazard to the fetus

[see Warnings and Precautions (5.3) and Use in Specific Populations (8.1)].

Recent major changes (as listed on the label)

Warnings and Precautions, Ototoxicity (5.2)

| 2/2023

|

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Questions about tobramycin 75 mg/ml inhalation solution

Who makes tobramycin 75 mg/ml inhalation solution?

3 companies: Lifestar Pharma LLC, NorthStar RxLLC, Prasco, LLC. See every package code.

Is tobramycin in shortage?

Yes - 1 product is listed as short or being discontinued. Details.

Has tobramycin been recalled?

27 recalls on record, 6 ongoing. Recalls name specific lots - check yours.

What does "pharmacies pay" mean?

It's the national average price retail pharmacies pay wholesalers and makers to buy the drug, from a weekly government survey of pharmacy invoices. It doesn't include the pharmacy's costs of filling a prescription, which is why the fair price adds a margin and a dispensing fee. How we work it out.

Talk about tobramycin 75 mg/ml inhalation solution

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.